Issuance of common stock is NT$428,679,000, the total paid-up capital is NT$700,000,000
BioGend approved the proposal of capital increase by cash on July 3, 2018. The current round of capital increase is mainly to enrich working capital, and it is ...
Biphasic Cartilage Repair Implant (RevoCart) Clinical Trial Has Successfully Completed Patient Enrollment
Exactech Taiwan is merged into BioGend
BioGend is recognized as a Biotech and New Pharmaceutical Company by Industrial Development Bureau (IDB)
BioGend Therapeutics signed the Australia and New Zealand exclusively distribution and co-development agreement
Osteo-inductive-factor (OIF)/TCP in rabbit ulnar defect model - CT
BioGend Therapeutics Capitalizes on Over NT$90 Billion in Opportunities in the Bone Grafting Market
Biphasic Cartilage Repair Implant (RevoCart)
The Biphasic Cartilage Repair Implant (RevoCart) is a type of articular cartilage regeneration and repair technique with autograft cartilage tissue.
At BioGend, we see opportunities that others have yet to identify — and we have the vision and determination to explore new frontiers, transforming ideas previously considered impossible into reality. We care patients with neglected needs and that’s why we hunger to provide breakthrough therapy in the basis of state-of-the-art science and innovative technology